Interestingly, ET A R blockade with zibotentan, a specific ET A R antagonist, or its silencing, downregulated Snail activity, restored drug sensitivity to cytotoxic-induced apoptosis, and inhibited the invasiveness of resistant cells. In vivo, zibotentan inhibited tumor growth of sensitive and resistant EOC xenografts, and sensitized to chemotherapy. Analysis of EOC human tissues revealed that ET A R is overexpressed in resistant tumors and is associated with EMT phenotype.
INTRODUCTION

Patient population
The study included 60 primary untreated ovarian cancer patients admitted to the Gynecologic Oncology Unit, Catholic University of Campobasso and Rome treated with platinum-based chemotherapy, plus paclitaxel. Further details were shown in Suppl. Materials and Methods.
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Author Manuscript Published OnlineFirst on January 10, 2011; DOI: 10.1158/1078-0432.CCR- Immunohistochemical analysis of ovarian cancers was performed on archival from 60 frozen tumors collected from patient population above described with informed consent, as indicated by Institutional Review Board, and classified according with WHO criteria. Further details were shown in Suppl. Materials and Methods.
Statistical Analysis
Statistical analysis was performed using Student's t test and Fisher's exact test as appropriate. The time course of tumor growth was compared across the groups using two-way ANOVA, with group and time as variables. All statistical tests were carried out using SPSS software (SPSS 11, SPSS Inc.
Chicago, IL). A two-sided probability value of <0.05 was considered statistically significant. 
RESULTS
Expression of ET-1/ET A R axis and activation of signaling pathways are upregulated in chemoresistant ovarian cancer cells
In order to assess the potential involvement of ET-1 axis in chemoresistance, we used the A2780 (WT) human EOC cell line, the derivative cisplatinum-resistant (A2780 CIS) and taxol-resistant (A2780 TAX) sublines, and the 2008 cell line and its cisplatinum-resistant variant 2008 CIS. The different sensitivity to these drugs was evident after treatment of serum-starved cells with the cytotoxic drugs, cisplatinum and taxol (Suppl. Fig. 1A ). In both A2780 and 2008 sensitive cells, cisplatinum or taxol treatment increased the number of early apoptotic cells, while in the resistant sublines the apoptotic pathway was compromised, confirming the acquisition of drug resistance in these cells.
The ET-1 axis is expressed in ovarian cancer cells acting as survival factor against chemotherapeutic drug treatment (12), suggesting that ET-1/ET A R axis would be upregulated in cisplatinum and taxol-resistant cells. As shown in fig 1A, B, and C and Suppl. Fig 2A, the cisplatinum-and taxol-resistant cells significantly expressed ET A R at higher levels compared to sensitive cells, and the concentrations of ET-1 released by resistant cells increased of about 8-fold compared to parental cells. All these data show that ET-1 axis is upregulated in EOC resistant cells correlating with the reduced sensitivity of these sublines to cytotoxic drugs.
We next determined the signalling pathways activated by ET-1/ET A R axis to modulate cell survival.
ET-1 activated both MAPK and Akt in sensitive A2780 cells, but a significant higher activation was observed in the resistant sublines that was inhibited when the cells were pretreated with the specific ET A R antagonist zibotentan (Fig. 1D) . Accordingly, ET-1 promoted A2780 cell proliferation, which was significantly inhibited in zibotentan-treated cells. To further verify the role of ET A R in regulating cell proliferation, we knock-down ET A R with siRNA and we found that also in ET A R- silenced cells the ET-1-induced cell proliferation was inhibited (Fig. 1E) . Specificity of siRNA oligos was confirmed by Western Blotting analysis, which showed a 90% knockdown of ET A R (Suppl. Fig. 2B ). These results suggest that in chemoresistant cells the higher activation of ET-1 axis lead to enhanced MAPK and Akt signalling pathways, which promote cell survival and proliferation.
Chemoresistant cells display molecular changes consistent with ET-1-driven EMT and invasiveness
Given the ability of ET-1 to promote EMT machinery in ovarian tumor cells and the association between chemoresistance and acquisition of EMT phenotype in different tumor cells (11, 19- 
we analyzed whether the chemoresistance in A2780 and 2008 cells was associated with molecular changes consistent with EMT and whether the ET A R pathway is involved in this process. To this end we examined the expression of E-cadherin and its transcriptional repressors, Snail, Slug and Twist, and other mesenchymal markers, such as vimentin and N-cadherin. Enhanced mRNA expression levels for Snail, Slug, Twist, vimentin and N-cadherin were observed in resistant sublines compared with parental cells, associated with a concomitant decrease in E-cadherin expression at level of mRNA and protein ( Fig. 2A and C) . Moreover, ET-1 enhanced the expression of Snail and Twist in both sensitive and resistant cells and the treatment with zibotentan inhibited the ET-1-induced effects, restoring E-cadherin expression ( Fig. 2B and 2C) . Remarkably, ET A R blockade, by both zibotentan or its silencing, reverted the ET-1-induced suppression of E-cadherin promoter activity and in resistant cells prevented that induced at higher level by endogenous ET-1/ET A R axis (Fig. 2D) , suggesting that the transcriptional regulation of E-cadherin may be important to ET A R-driven EMT and acquisition of chemoresistance. In agreement with above results, ET-1 induced significant induction of Snail promoter activity in parental cells, reaching about 4-fold increase in resistant cells, which was significantly inhibited by zibotentan (Fig. 2E 
aggressive phenotype of chemoresistant cells, is therapeutic effective in resistant EOC cells, increasing sensitivity to the chemotherapy.
ET A R is overexpressed in resistant human ovarian tumors
Finally we analyzed the importance of ET A R as potential marker of resistance in human EOC tissues from patients treated with platinum-based chemotherapy, plus paclitaxel.
Clinicopathological characteristics of the overall series are summarized in Table 1 . Forty-seven cases (78.3%) were stage III-IV disease, and serous histotype was documented in the vast majority (n = 44, 73.3%) of cases. Optimal cytoreduction (residual tumor <1 cm) was achieved in 32 (53.3%) patients. Thirty-one (51.7%) cases were defined as platinum resistant, while 29 patients (48.3%) were platinum sensitive. Patients optimally cytoreduced at first surgery were more likely to be platinum sensitive compared to patients judged as unresectable (62.5% vs 32.1%, p value=0.017). Patients with no ascites were more frequently platinum sensitive than patients with ascites at primary laparotomy (66.7% vs 33.3%, p value=0.018). We analysed the ET A R levels by immunohistochemistry in these human ovarian cancer specimens encompassing platinum sensitivity and platinum resistance. Overall, ET A R was significantly upregulated in 66% (p< 0.017) of resistant ovarian cancers compared to sensitive tumors (Table 1 and Fig 5D) . Consistent with our observations in EOC cell cultures and xenografts, overexpression of ET A R in platinum-resistant human ovarian cancer tissues was associated with the downregulation of E-cadherin (p<0.002) and with enhanced expression of mesenchymal N-cadherin (p<0.07; Fig. 5D ). These results are consistent with our previous findings in primary ovarian tumor tissues (10) metastatic lesions (30) (31) (32) (33) . Moreover, it was reported that cellular morphology, motility, and molecular changes consistent with EMT, including enhanced Snail and Twist expression, were related to paclitaxel-resistance in EOC cells (34, 35) . Recent work has suggested that may be a link between the cancer stem cell (CSC) phenotype and that induced by the process of EMT (36) . The CSC isolated from EOC samples express markers associated with stem cells and EMT, including Snail and Slug, suggesting that EOC cells, by going through an EMT, acquire stemness characteristics qualifying them to acquire chemoresistance by overcoming p53-mediated apoptosis 
